Clinical Research Trials and Studies

These aid in finding treatments and cures for various visual conditions and diseases. Clinical research can be funded either through private or government entities. All clinical research supported by the National Eye Institute is conducted through our Vision Research Laboratories.

The New England Eye Center also participates in corporate or privately sponsored clinical trials that are administered through its various specialties.

For more details about any of these trials or studies, or, to participate, please call the study coordinator listed.

Trials

AGE-RELATED MACULAR DEGENERATION (AMD)

EPI-RAD90™ Ophthalmic System vs. Lucentis®

Target Population: Males and females, 50 years and older, with newly diagnosed or untreated AMD
Study Duration: 3 years
Description: The purpose of this study is to determine whether an investigational device, called Epi-Rad90™ Ophthalmic System, is effective and safe for use in wet age-related macular degeneration. Subjects will receive either a dose of radiation to their eye from the Epi-Rad plus a drug called Lucentis® or they will receive eye injections of Lucentis® only. Lucentis® is a FDA approved drug for the treatment of AMD.

DIABETIC MACULAR EDEMA (DME)

PF-04523655 vs. LASER

Target Population: Males and females, 18 years and older, with DME
Study Duration: 3 years
Description: The purpose of this study is to evaluate the safety and effectiveness of an investigational drug, known as PF-04523655, for use in diabetic macular edema.  Subjects will either receive 1 of 3 doses of the study drug or they will receive laser treatment to their eye.  PF-04523655 is given as an eye injection.

Julie S. Burt
Supervisor, Ophthalmology Clinical Trials and Regulatory Affairs
New England Eye Center
Tufts Medical Center
800 Washington Street, #450
Boston, MA 02111
617-636-0747 Fax: 617-636-4866
Email:  jburt@tuftsmedicalcenter.org

 

Studies

AGE-RELATED MACULAR DEGENERATION (AMD)

Etiologic Studies of Age Related Macular Degeneration

Principal Investigator: Johanna M. Seddon, MD., ScM
Professor of Ophthalmology at Tufts University School of Medicine
Founding Director of the Ophthalmic Epidemiology and Genetics Service
of Tufts Medical Center

Definition: AMD is a retinal degenerative disease that causes a progressive loss of central vision. AMD is the most common cause of vision loss in individuals age 60 years and older.

Target Population: Individuals with advanced stages of macular degeneration (wet or dry) over age 55 and their spouses, siblings and adult children (with or without AMD). Also recruiting individuals without signs of AMD.

Duration: On-going since 1989.

Purpose: The purpose of this research study is to determine the causes of macular degeneration so we can prevent it and find better treatments. We will identify genes and environmental determinants of AMD. Eligible study participants will have an eye exam and blood draw. Participants will also complete questionnaires on diet and risk factors.

Recent discoveries by our research team and collaborators: Four novel genetic variants associated with AMD including Hepatic Lipase C, a gene associated with reduced risk of AMD; TIMP3, a gene related to AMD; complement proteins in plasma (in the inflammatory pathway) are associated with AMD; higher total cholesterol and higher LDL levels increase risk of AMD, and higher HDL reduces risk.

YOU DO NOT NEED TO LIVE IN THE BOSTON AREA TO PARTICIPATE.

Robyn Reynolds
Project Manager
Ophthalmic Epidemiology and Genetics Service
New England Eye Center
Tufts Medical Center
800 Washington Street #450
Boston, MA  02111
617-636-9000
or
Toll Free: 800-219-9157

spacer